Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr60.25 SEK
Change Today +2.95 / 5.15%
Volume 1.5M
EKTAB On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Frankfurt
As of 6:16 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

elekta ab-b shs (EKTAB) Snapshot

Open
kr57.50
Previous Close
kr57.30
Day High
kr60.75
Day Low
kr56.85
52 Week High
01/26/15 - kr91.20
52 Week Low
06/29/15 - kr50.65
Market Cap
23.1B
Average Volume 10 Days
1.5M
EPS TTM
kr1.45
Shares Outstanding
368.6M
EX-Date
09/2/15
P/E TM
41.7x
Dividend
kr0.50
Dividend Yield
3.31%
Current Stock Chart for ELEKTA AB-B SHS (EKTAB)

Related News

No related news articles were found.

elekta ab-b shs (EKTAB) Related Businessweek News

No Related Businessweek News Found

elekta ab-b shs (EKTAB) Details

Elekta AB (publ), develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend sytem for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualize tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; and METRIQ, a cancer registry data solution. It also offers installation and implementation, service and support, remote, upgrades and accessories, and financial solutions, as well as training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

3,844 Employees
Last Reported Date: 06/2/15
Founded in 1972

elekta ab-b shs (EKTAB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

elekta ab-b shs (EKTAB) Key Developments

Elekta AB Announces Executive Appointments

Elekta AB appointed Johan Malmqvist and Annika Espander Jansson as directors of the Board. Annika Espander Jansson has 25 years' experience as an analyst and investor, as well as from executive positions within the financial markets and the pharmaceutical industry. She is the founder of Asperia AB and has been the CEO since June 2013. Johan Malmqvist has extensive experience from the medical technology industry. Johan Malmqvist was born in 1961 and holds a BA from Stockholm School of Economics. From 1997 to 2015, he was president and CEO of Getinge AB.

Todd Powell to Assume as Elekta's Executive Vice President, Comprehensive Oncology Solutions

Elekta announced that Todd Powell will soon assume the role of Elekta's executive vice president, Comprehensive Oncology Solutions.

Elekta AB Announces CE Mark for its Leksell Gamma Knife Icon

Elekta AB announced that it has CE marked its Leksell Gamma Knife Icon precision radiosurgery system, making this latest generation Leksell Gamma Knife platform available in the European market. The Icon, with stereotactic imaging, online Adaptive DoseControl, ultra-precise dose delivery and the availability of frameless treatments, is capable of treating virtually any target in the brain, regardless of type, location or volume. In addition, Elekta has reportedly submitted Leksell Gamma Knife Icon for US FDA 510(k) clearance.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKTAB:SS kr60.25 SEK +2.95

EKTAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Accuray Inc $6.33 USD -0.05
Eckert-Ziegler Bebig €1.15 EUR -0.039
Icad Inc $3.35 USD -0.07
MRI Interventions Inc $0.71 USD -0.2249
RaySearch Laboratories AB kr122.75 SEK +2.25
View Industry Companies
 

Industry Analysis

EKTAB

Industry Average

Valuation EKTAB Industry Range
Price/Earnings 38.2x
Price/Sales 1.9x
Price/Book 3.2x
Price/Cash Flow 37.0x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEKTA AB-B SHS, please visit www.elekta.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.